Vilga Financial Planning LLC Acquires 22,000 Shares of Abivax SA Sponsored ADR $ABVX

Vilga Financial Planning LLC bought a new stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, HoldingsChannel.com reports. The institutional investor bought 22,000 shares of the company’s stock, valued at approximately $2,178,000. Abivax makes up approximately 1.3% of Vilga Financial Planning LLC’s investment portfolio, making the stock its 21st largest position.

Other hedge funds also recently bought and sold shares of the company. Lord Abbett & CO. LLC increased its stake in Abivax by 152.4% in the 4th quarter. Lord Abbett & CO. LLC now owns 849,732 shares of the company’s stock worth $114,591,000 after buying an additional 513,026 shares in the last quarter. Eversept Partners LP lifted its position in shares of Abivax by 42.0% in the first quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock valued at $104,048,000 after acquiring an additional 276,589 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Abivax by 31.6% in the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after acquiring an additional 211,068 shares during the period. Bank of America Corp DE grew its position in shares of Abivax by 40.9% during the first quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock worth $81,923,000 after purchasing an additional 213,440 shares in the last quarter. Finally, Two Seas Capital LP purchased a new stake in shares of Abivax during the third quarter worth about $66,996,000. Institutional investors own 47.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. BTIG Research boosted their price target on Abivax from $150.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating and set a $180.00 price objective on shares of Abivax in a research report on Friday, July 24th. Truist Financial lowered their target price on shares of Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Leerink Partners upped their target price on shares of Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Finally, Barclays reaffirmed an “overweight” rating and issued a $148.00 price objective on shares of Abivax in a research note on Tuesday, September 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and an average price target of $156.69.

Abivax Stock Up 2.3%

Abivax stock opened at $89.05 on Friday. The company’s 50-day moving average price is $111.22 and its 200-day moving average price is $115.50. The company has a market cap of $7.78 billion, a PE ratio of -14.69 and a beta of 1.14. Abivax SA Sponsored ADR has a twelve month low of $69.81 and a twelve month high of $148.83.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, September 21st. The company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, sell-side analysts expect that Abivax SA Sponsored ADR will post -4.18 earnings per share for the current fiscal year.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. The company’s lead investigational product is obefazimod, an oral small-molecule treatment being developed for ulcerative colitis, a chronic inflammatory disease of the colon.

Obefazimod, formerly known as ABX464, is designed to increase levels of microRNA-124, a molecule involved in regulating inflammatory responses. Abivax is evaluating the therapy in late-stage clinical studies for ulcerative colitis and has also investigated its potential in other inflammatory conditions, including Crohn’s disease.

Founded in 2013 and headquartered in Paris, France, Abivax conducts its development activities through international clinical programs and serves the global biopharmaceutical market.